New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism

BACKGROUND: Vandetanib is the first US Food and Drug Administration approved agent to treat advanced or metastasized thyroid cancer. To gain a better understanding of the drug, we conducted a systematic review of its efficacy and safety in patients with thyroid cancers. METHODS: Trial data was retri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huan-gao, Zhao, Jun-yu, Zhang, Rui, Liao, Lin, Dong, Jian-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511335/
https://www.ncbi.nlm.nih.gov/pubmed/26273412
http://dx.doi.org/10.1111/1759-7714.12238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511335/
https://www.ncbi.nlm.nih.gov/pubmed/26273412
http://dx.doi.org/10.1111/1759-7714.12238

Ejemplares similares